TherapeuticsMD (TXMD) Competitors $1.12 +0.03 (+2.28%) Closing price 03:59 PM EasternExtended Trading$1.12 -0.01 (-0.89%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. ANVS, ATNM, KPTI, BRNS, NRXP, LTRN, VTVT, PRLD, COEP, and IPSCShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Annovis Bio (ANVS), Actinium Pharmaceuticals (ATNM), Karyopharm Therapeutics (KPTI), Barinthus Biotherapeutics (BRNS), NRx Pharmaceuticals (NRXP), Lantern Pharma (LTRN), vTv Therapeutics (VTVT), Prelude Therapeutics (PRLD), Coeptis Therapeutics (COEP), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Its Competitors Annovis Bio Actinium Pharmaceuticals Karyopharm Therapeutics Barinthus Biotherapeutics NRx Pharmaceuticals Lantern Pharma vTv Therapeutics Prelude Therapeutics Coeptis Therapeutics Century Therapeutics TherapeuticsMD (NASDAQ:TXMD) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Does the media refer more to TXMD or ANVS? In the previous week, Annovis Bio had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for TherapeuticsMD. Annovis Bio's average media sentiment score of 0.42 beat TherapeuticsMD's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media. Company Overall Sentiment TherapeuticsMD Neutral Annovis Bio Neutral Do institutionals and insiders hold more shares of TXMD or ANVS? 30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 2.3% of TherapeuticsMD shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is TXMD or ANVS more profitable? Annovis Bio has a net margin of 0.00% compared to TherapeuticsMD's net margin of -17.94%. TherapeuticsMD's return on equity of -2.01% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-17.94% -2.01% -1.40% Annovis Bio N/A -206.01%-158.26% Which has preferable earnings & valuation, TXMD or ANVS? TherapeuticsMD has higher revenue and earnings than Annovis Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$2.56M5.09-$2.18MN/AN/AAnnovis BioN/AN/A-$24.59M-$2.04-1.10 Do analysts prefer TXMD or ANVS? Annovis Bio has a consensus target price of $18.00, suggesting a potential upside of 703.57%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, TXMD or ANVS? TherapeuticsMD has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. SummaryAnnovis Bio beats TherapeuticsMD on 8 of the 13 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.02M$2.78B$5.75B$9.73BDividend YieldN/A1.67%4.40%4.10%P/E RatioN/A22.2430.2525.89Price / Sales5.09749.20474.39123.10Price / CashN/A26.0925.7828.79Price / Book0.475.539.426.00Net Income-$2.18M$31.83M$3.27B$265.29M7 Day Performance-1.32%1.07%2.08%2.59%1 Month Performance-5.46%0.83%3.63%0.98%1 Year Performance-36.44%7.24%30.13%18.75% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.1446 of 5 stars$1.13+2.3%N/A-37.9%$13.02M$2.56M0.00420ANVSAnnovis Bio2.2374 of 5 stars$2.70-1.6%$18.00+567.9%-75.4%$53.39MN/A-1.323ATNMActinium Pharmaceuticals2.4635 of 5 stars$1.71+1.2%$4.50+163.2%-13.4%$53.35MN/A-1.2330KPTIKaryopharm Therapeutics3.7835 of 5 stars$5.59-5.6%$34.00+508.2%-49.6%$51.33M$137.27M-0.38380BRNSBarinthus Biotherapeutics2.9702 of 5 stars$1.19-4.0%$3.00+152.1%+0.0%$50.02M$14.97M-0.69107Positive NewsGap UpNRXPNRx Pharmaceuticals3.0819 of 5 stars$2.76-4.5%$28.50+932.6%+26.9%$49.97MN/A-1.372Earnings ReportHigh Trading VolumeLTRNLantern Pharma2.628 of 5 stars$4.44-2.8%$25.00+463.1%-3.0%$49.35MN/A-2.4920VTVTvTv Therapeutics1.55 of 5 stars$15.48+0.2%$35.50+129.4%-9.1%$49.32M$1.02M-4.969Gap DownHigh Trading VolumePRLDPrelude Therapeutics2.7982 of 5 stars$0.94+8.5%$4.00+323.7%-76.9%$49.24M$7M-0.58120Gap UpCOEPCoeptis Therapeutics0.7086 of 5 stars$14.65+4.9%N/A+228.3%$49.09MN/A-2.532Positive NewsIPSCCentury Therapeutics3.0026 of 5 stars$0.57+2.2%$3.75+552.9%-69.8%$48.40M$6.59M-1.98170 Related Companies and Tools Related Companies Annovis Bio Alternatives Actinium Pharmaceuticals Alternatives Karyopharm Therapeutics Alternatives Barinthus Biotherapeutics Alternatives NRx Pharmaceuticals Alternatives Lantern Pharma Alternatives vTv Therapeutics Alternatives Prelude Therapeutics Alternatives Coeptis Therapeutics Alternatives Century Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access